

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGE IN COMPOSITION OF BOARD COMMITTEES AND COMPLIANCE WITH RULES 3.10(1), 3.10A AND 3.21 OF THE LISTING RULES

References are made to the announcements of Clarity Medical Group Holding Limited (the “**Company**”) dated 8 February 2024 and 14 May 2024 (the “**Announcements**”) in relation to the passing away of Professor Lau and the grant of waiver and an extension of time for complying with Rules 3.10(1), 3.10A and 3.21 of the Listing Rules for the appointment of an independent non-executive Director. Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the Announcements.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Cheng Jessica (“**Ms. Cheng**”) has been appointed as an independent non-executive Director with effect from 29 May 2024.

The biological details of Ms. Cheng are set out below:

Ms. Cheng, aged 43, has over 17 years in the medical industry. Ms. Cheng is currently a managing partner of Chief Sound Industries Limited, an electronics manufacturing company in the People's Republic of China (the "PRC"); a consultant at Genesis Medical Technology (Shanghai) Company Limited, an international medical device company; and an advisory partner at MCM Partners, a global merchant bank, corporate advisor and asset management firm headquartered in Hong Kong.

Previously, Ms. Cheng held the position of President of the Greater Bay Area at Genesis GBA Limited, an international medical device company from 2021 to 2023. Ms. Cheng also served as an independent consultant to BGI Health (HK) Company Limited, a subsidiary of BGI Genomics, a world-leading genomics company listed on the Shenzhen Stock Exchange (stock code: 300676). Between 2018 and 2020, Ms. Cheng served as the chief operating officer in the Greater Bay Area and chief operating officer for the Strategic Investment Department at WeDoctor (Hong Kong) Limited, a technology-enabled healthcare solutions platform in the PRC. Prior to the above, Ms. Cheng worked in both commercial firms and government statutory bodies in the medical sector, including serving as the manager of the chairman and chief executive's office of the Hong Kong Hospital Authority from 2009 to 2014.

Ms. Cheng obtained a Bachelor of Business Administration degree from the University of Kent (formally known as the University of Kent at Canterbury), United Kingdom, in 2001, and a Master of Science degree in Training and Human Resource Management from the University of Leicester, United Kingdom, in 2010.

Ms. Cheng's contributions to the community extends beyond her professional endeavours. Ms. Cheng is currently a member of the 13th Guangdong Provincial Committee of the Chinese People's Political Consultative Committee; Deputy Director of Medicine & Health Committee of Council for the Promotion of Guangdong-Hong Kong-Macao Cooperation; Member of the Hospital Governing Committee of the Pamela Youde Nethersole Eastern Hospital in Hong Kong; Honorary Secretary of the Little Life Warrior Society, a non-profit charitable organisation that supports children cancer patients and their families; and a Member of the Lung Tong Area Committee in the Kowloon City District of Hong Kong.

Pursuant to the letter of appointment entered into between the Company and Ms. Cheng, Ms. Cheng is appointed as an independent non-executive Director for an initial term of three years commencing from 29 May 2024. The term of service of Ms. Cheng is subject to retirement by rotation in accordance with the articles of association of the Company and the Listing Rules. Ms. Cheng is entitled to receive a fixed director's remuneration of HK\$300,000 per annum, which was recommended by the remuneration committee of the Company and determined by the Board, with reference to her responsibilities, experience and market rate of directors' remuneration of listed companies of a comparable size of operation.

Save as disclosed above, Ms. Cheng (i) did not hold any other directorship in other listed companies during the past three years; (ii) does not hold any position of the Company or any of its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as at the date of this announcement.

Ms. Cheng has confirmed that she has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, neither is there any further information required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter relating to the appointment of Ms. Cheng that needs to be brought to the attention of the shareholders of the Company.

The Company would like to express its warmest welcome to Ms. Cheng in joining the Board.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Ms. Cheng has been appointed by the Board as a member of the Audit Committee with effect from 29 May 2024.

COMPLIANCE WITH RULES 3.10(1), 3.10A AND 3.21 OF THE LISTING RULES

Following the appointment of Ms. Cheng as an independent non-executive Director, the Board comprises three executive Directors, three non-executive Directors and three independent non-executive Directors. As a result, the Company complies with the requirements under Rules 3.10(1), 3.10A and 3.21 of the Listing Rules in respect of the minimum number of independent non-executive Directors and the minimum number of members of the Audit Committee.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 29 May 2024

As at the date of this announcement, the Board comprises Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. NG Roy and Ms. ZHAO Wei as non-executive Directors, Mr. LI Michael Hankin, Mr. MA Wai Hung Vincent and Ms. CHENG Jessica as independent non-executive Directors.